Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07042100 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
A Phase 1 study of Advanced Solid Tumors, sponsored by Sun Pharma Advanced Research Company Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 177
- Enrollment target
- 11
- Study locations
NCT07042100: Recruiting Phase 1 study of Advanced Solid Tumors, sponsored by Sun Pharma Advanced Research Company Limited.
NCT07042100 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 177 participants, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07042100, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Sun Pharma Advanced Research Company Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 177 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
Primary Outcome
Applicable to Part 1 only
Conditions Studied
Interventions
- BIOLOGICAL Dose level (DL)1
- BIOLOGICAL DL2
- BIOLOGICAL DL3
- BIOLOGICAL DL4
- BIOLOGICAL DL5
Study Locations (11)
Maharashtra
- Tata Memorial hospital - Mumbai
- Noble Hospital Pvt. Ltd. - Pune
Arizona
- Honorhealth Research Institute - Scottsdale
California
- Sarcoma Oncology Research Center - Santa Monica
Connecticut
- Yale University - Yale Cancer Center - New Haven
Illinois
- Hope And Healing Cancer Services, Llc - Hinsdale
Texas
- MD Anderson Cancer Center - Houston
New South Wales
- Scientia Clinical Research - Randwick
Queensland
- Sunshine Coast University Private Hospital - Birtinya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
What NCT07042100 shows while recruiting
NCT07042100 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Dose level (DL)1 is the first listed.
NCT07042100 lists 11 locations in 10 states (Maharashtra, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT07042100 about?
NCT07042100 is a clinical study titled "A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.". This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.
What is the current status of trial NCT07042100?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 177 participants. The study started on 2025-08-12. Estimated completion is 2030-08.
What conditions does trial NCT07042100 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07042100?
The interventions under investigation include: Dose level (DL)1 (BIOLOGICAL), DL2 (BIOLOGICAL), DL3 (BIOLOGICAL), DL4 (BIOLOGICAL), DL5 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07042100?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07042100 being conducted?
This trial has 11 study locations across Arizona, California, Connecticut, Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07042100's enrollment target sits among peer trials
177 50th of 144 higher than 95 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI